138,000 Shares in Atyr PHARMA INC (NASDAQ:ATYR) Acquired by OMERS ADMINISTRATION Corp

OMERS ADMINISTRATION Corp acquired a new position in Atyr PHARMA INC (NASDAQ:ATYR - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 138,000 shares of the company's stock, valued at approximately $500,000. OMERS ADMINISTRATION Corp owned 0.16% of Atyr PHARMA as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the stock. Octagon Capital Advisors LP acquired a new stake in Atyr PHARMA in the fourth quarter worth about $3,258,000. Millennium Management LLC bought a new stake in Atyr PHARMA in the fourth quarter worth about $1,332,000. Integral Health Asset Management LLC bought a new stake in Atyr PHARMA in the fourth quarter worth about $1,358,000. J. Goldman & Co LP bought a new stake in Atyr PHARMA in the fourth quarter worth about $1,086,000. Finally, Jefferies Financial Group Inc. bought a new stake in Atyr PHARMA in the fourth quarter worth about $201,000. Institutional investors and hedge funds own 61.72% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on ATYR. Leerink Partners began coverage on shares of Atyr PHARMA in a research report on Tuesday, February 18th. They issued an "outperform" rating and a $16.00 price target on the stock. HC Wainwright reiterated a "buy" rating and issued a $35.00 price target on shares of Atyr PHARMA in a research report on Monday, May 19th. Finally, Leerink Partnrs upgraded Atyr PHARMA to a "strong-buy" rating in a report on Tuesday, February 18th. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $18.60.

Atyr PHARMA Stock Down 1.3%

Shares of ATYR traded down $0.05 during trading hours on Friday, reaching $3.75. The company's stock had a trading volume of 991,820 shares, compared to its average volume of 931,298. The firm has a market cap of $333.77 million, a price-to-earnings ratio of -3.99 and a beta of 0.79. Atyr PHARMA INC has a 1-year low of $1.42 and a 1-year high of $4.66. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.02. The company has a 50 day moving average of $3.24 and a two-hundred day moving average of $3.42.

Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported ($0.17) earnings per share for the quarter, beating analysts' consensus estimates of ($0.19) by $0.02. As a group, research analysts predict that Atyr PHARMA INC will post -0.91 EPS for the current fiscal year.

Atyr PHARMA Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.